- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07659236
The Potential Application of Plasma-Activated Water in Fibromyalgia Patients
Fibromyalgia is a chronic syndrome characterized by widespread pain that is commonly observed in pain, rheumatology, or rehabilitation clinics. Previous studies have suggested a fibromyalgia prevalence rate of approximately 2%. Currently, evidence shows that fibromyalgia might be partially associated with increased oxidative stress, caused by mitochondrial abnormalities, genetic abnormalities, and excessive metal intake. Some research teams have experimented with dietary adjustments to control oxidative stress, but the relationship between diet and oxidative stress has not been conclusively confirmed.
Plasma-activated water is a method of storing the high-energy benefits of water and effectively utilizing its energy. It also improves solubility and conductivity at room temperature. It involves activating nano gold particles with a specific wavelength light source to create surface plasmon resonance, resulting in thermoelectrons. These thermoelectrons then disrupt or reduce the hydrogen bonding capacity between water molecules in the tetrahedral chemical structure network, leading to the formation of smaller water molecules known as plasma-activated water.
Studies on animals have shown that plasma-activated water possesses free radical-scavenging and antioxidant properties. It can reduce liver oxidative stress damage induced by sleep deprivation and is non-toxic. Recent studies have shown that plasma-activated water can treat cancer, chronic diseases, and degenerative conditions in animal models. In a lung cancer animal model, combining plasma-activated water with cisplatin chemotherapy increased the mice's survival time. In an animal model with chronic kidney disease, drinking plasma-activated water reduced fibronectin expression and slowed kidney fibrosis. Plasma-activated water reduced oxidative stress in an animal model of chronic sleep deprivation-induced liver damage, thereby enhancing the antioxidant and anti-inflammatory capabilities of the liver cells. In an animal model with Alzheimer's disease, it reduced amyloid-β protein expression and improved memory. In a rat model with Parkinson's disease, plasma-activated water suppressed inflammation and protected nerve cells.
Since plasma-activated water has demonstrated antioxidant effects in mouse and rat animal models and previous clinical trials have shown that drinking plasma-activated water does not have toxic reactions and does not significantly affect drug metabolism in the human body, this study aims to assess the safety and potential symptom improvement effects of long-term consumption of plasma-activated water in fibromyalgia patients.
Studienübersicht
Status
Intervention / Behandlung
Studientyp
Einschreibung (Geschätzt)
Phase
- Unzutreffend
Kontakte und Standorte
Studienorte
-
-
-
Taipei, Taiwan, 110
- Rekrutierung
- Taipei Medical University Hospital
-
Kontakt:
- Jiunn-Horng Kang, MD, PhD
- Telefonnummer: 3242 +886-2-27372181
- E-Mail: jhk@tmu.edu.tw
-
Hauptermittler:
- Jiunn-Horng Kang, MD, PhD
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
- Erwachsene
- Älterer Erwachsener
Akzeptiert gesunde Freiwillige
Beschreibung
Inclusion Criteria:
- Currently experiencing widespread bodily pain for a duration of at least three months and diagnosed by a clinical specialist as a fibromyalgia patient.
- Aged between 20 and 75 years.
- Clear understanding and the ability to communicate with the researchers in Mandarin or Taiwanese dialect through spoken or written language.
- Willingness to participate in this research after receiving an explanation and the ability to cooperate with the research procedures.
Exclusion Criteria:
- Malignant tumors.
- Currently experiencing an acute infection.
- Concurrent central nervous system disorders such as stroke or Parkinson's disease.
- Concurrent endocrine system disorders such as hypothyroidism.
- Significant autoimmune diseases such as rheumatoid arthritis, ankylosing spondylitis, lupus, and others.
- Currently pregnant.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Nicht randomisiert
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Fibromyalgia Patients with Plasma-Activated Water Use
|
Plasma-activated water is a method of storing the high-energy benefits of water and effectively utilizing its energy.
It also enhances properties such as solubility and conductivity at room temperature.
It involves activating nano gold particles with a specific wavelength light source to create surface plasmon resonance, resulting in thermoelectrons.
These thermoelectrons then disrupt or reduce the hydrogen bonding capacity between water molecules in the tetrahedral chemical structure network, leading to the formation of smaller water molecules known as plasma-activated water.
|
|
Placebo-Komparator: Fibromyalgia Patients with Placebo Use
|
Typical drinking water
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Fasting Blood Levels of Selected Laboratory Biomarkers
Zeitfenster: Pre-test visit, after at least 6 hours of fasting
|
Blood samples will be collected after participants have fasted for at least 6 hours.
Samples will be analyzed for selected laboratory biomarkers, including glucose, total cholesterol, triglycerides, HDL cholesterol, LDL cholesterol, creatinine, alanine aminotransferase (ALT), aspartate aminotransferase (AST), and/or other prespecified analytes.
Glucose, total cholesterol, triglycerides, HDL cholesterol, and LDL cholesterol will be reported in mg/dL; creatinine will be reported in mg/dL; and ALT and AST will be reported in U/L.
|
Pre-test visit, after at least 6 hours of fasting
|
Mitarbeiter und Ermittler
Sponsor
Publikationen und hilfreiche Links
Allgemeine Veröffentlichungen
- Sanchez-Dominguez B, Bullon P, Roman-Malo L, Marin-Aguilar F, Alcocer-Gomez E, Carrion AM, Sanchez-Alcazar JA, Cordero MD. Oxidative stress, mitochondrial dysfunction and, inflammation common events in skin of patients with Fibromyalgia. Mitochondrion. 2015 Mar;21:69-75. doi: 10.1016/j.mito.2015.01.010. Epub 2015 Feb 7.
- Rus A, Robles-Fernandez I, Martinez-Gonzalez LJ, Carmona R, Alvarez-Cubero MJ. Influence of Oxidative Stress-Related Genes on Susceptibility to Fibromyalgia. Nurs Res. 2021 Jan/Feb;70(1):44-50. doi: 10.1097/NNR.0000000000000480.
- Tel Adiguzel K, Koroglu O, Yasar E, Tan AK, Samur G. The relationship between dietary total antioxidant capacity, clinical parameters, and oxidative stress in fibromyalgia syndrome: A novel point of view. Turk J Phys Med Rehabil. 2022 Jun 1;68(2):262-270. doi: 10.5606/tftrd.2022.9741. eCollection 2022 Jun.
- Chen HC, Yang CP, Hong CT, Hsu CT, Hu CC, Liu YC. Potential of Plasmon-Activated Water as a Comprehensive Active Green Energy Resource. ACS Omega. 2019 May 2;4(5):8007-8014. doi: 10.1021/acsomega.9b00463. eCollection 2019 May 31.
- Yang CP, Liu YC. Therapeutics for Inflammatory-Related Diseases Based on Plasmon-Activated Water: A Review. Int J Mol Sci. 2018 May 28;19(6):1589. doi: 10.3390/ijms19061589.
- Cheng CH, Lin KJ, Hong CT, Wu D, Chang HM, Liu CH, Hsiao IT, Yang CP, Liu YC, Hu CJ. Plasmon-Activated Water Reduces Amyloid Burden and Improves Memory in Animals with Alzheimer's Disease. Sci Rep. 2019 Sep 13;9(1):13252. doi: 10.1038/s41598-019-49731-8.
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Andere Studien-ID-Nummern
- N202311061
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .